U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07196306) titled 'Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19' on May 07, 2020.
Brief Summary: Studying the efficacy of IL-6 inhibition utilizing single or double dose subcutaneous administration of Sarilumab in patients with severe respiratory distress caused by COVID19 regarding improvement in oxygen demands and other clinical outcomes.
Study Start Date: May 07, 2020
Study Type: INTERVENTIONAL
Condition:
COVID
COVID-19
Corona Virus Infection
Intervention:
DRUG: Sarilumab 200 MG/1.14 ML Subcutaneous Solution
At the time of enrollment, the intervention arm subjects are administered s...